NSE: AJANTPHARM | BSE: 532331

Mid-range Performer

Download real time

2579.10 7.10 (0.28%)

25.99% Fall from 52W High

60,304 NSE+BSE Volume

NSE 12 Sep, 2025 3:31 PM (IST)

32,216.1

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Ajanta Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AJANTPHARM, BSE:532331 Ajanta Pharma Ltd.

Ajanta Pharma Ltd.

25 Jan 2017

2579.10

0.28%

Ajanta Pharma Ltd Q3FY17 results comment

Results Update: Ajanta Pharma Ltd.

HDFC Securities

Revenue increased by 2.52% to Rs. 515.02 Cr in Q3FY17 when compared to the previous quarter. Also, it increased by 9.68% when compared with Q3FY16

Ajanta Pharma Ltd. has an average target of 3022.00 from 5 brokers.

Ajanta Pharma Ltd.

25 Jan 2017

2579.10

0.28%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Revenues grew 12% YoY to | 533 crore (I-direct estimate: | 578 crore) on the back of 15% growth in domestic sales to | 154 crore (Idirect estimate: | 157 crore). Export formulations grew 9% YoY to | 361 crore (I-direct estimate: | 408 crore). The sharp growth in the US was largely offset by the decline in Asia EBITDA margins declined 100 bps YoY to 33.4% (I-direct estimate: 35.0%) mainly due to higher other expenditure Net profit increased 25% YoY to | 143 crore (I-direct estimate: | 145 crore) mainly due to forex gain of | 10 crore and lower taxation...

Promoters pledged 1.51% of shares in last quarter. Total pledge stands at 14.12% of promoter holdings

Ajanta Pharma Ltd.

27 Oct 2016

2579.10

0.28%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Recommendation Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 18% YoY to | 516 crore (I-direct estimate: | 513 crore) on back of 21% growth in domestic sales to | 158 crore (Idirect estimate: | 155 crore). Export formulation grew 14% to | 345 crore (I-direct estimate: | 339 crore) on a sharp jump in US sales. US sales rose to | 71 crore vs. | 2 crore, | 10 crore in Q2FY16, Q1FY17, respectively. Asia, Africa sales, on the other hand, were muted EBITDA margins declined 157 bps to 33.6% (I-direct estimates: 34.0%) mainly due to forex loss of | 9.84 crore...

Number of FII/FPI investors decreased from 385 to 371 in Jun 2025 qtr

Ajanta Pharma Ltd.

27 Jul 2016

2579.10

0.28%

Ajanta Pharmaceuticals

Hold: Ajanta Pharma Ltd.

Recommendation

ICICI Securities Limited

Revenues grew 20.4% YoY to | 471 crore (I-direct estimate: | 455 crore) on the back of 18.6% growth in exports to | 287 crore (I-direct estimate: | 292 crore). Domestic sales grew 9.5% to | 162 crore (Idirect estimate: | 149 crore) .EBITDA margins increased 406 bps YoY to 35.4% (I-direct estimates: 32.0%) on account of gross margin expansion. Gross margins increased 532 bps YoY to 78.9% ((I-direct estimates: 75.5%). EBITDA increased 36.0% YoY to | 166.6 crore .Net profit increased 33.5% YoY to | 120 crore, (I-direct estimate: | 101 crore) on the back of a robust operational performance. ICICI Securities Limited maintain target of | 1780 based on 28x FY18E EPS of | 63.5. At the current level, the stock has already factored in the near term upside.

Trendlyne has 6 reports on AJANTPHARM updated in the last year from 2 brokers with an average target of Rs 1712. Brokers have a rating for AJANTPHARM with 1 downgrade in past 6 months and 1 price downgrades,1 price upgrade in past 1 Year.

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

02 May 2016

2579.10

0.28%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

ICICI Securities Limited

Number of FII/FPI investors decreased from 385 to 371 in Jun 2025 qtr

Ajanta Pharma Ltd.

03 Feb 2016

2579.10

0.28%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

ICICI Securities Limited

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

09 Jul 2015

2579.10

0.28%

Ajanta Pharma - Stock Idea

Buy: Ajanta Pharma Ltd.

Systematix Group

Established in 1973, Ajanta Pharma (APL) is a specialty pharmaceutical company engaged in development, manufacture and marketing of quality finished dosages in domestic and international markets. The company has 5 state-of-the art manufacturing facilities. Ajanta has extensive presence in many countries in Asia, Africa and Latin America employing over 4,000 people worldwide and its products sold in over 50 countries. The company has also started commercial operations in the US market in the first quarter of 2013 which it plans to scale up in the coming couple of years. APL has improved its ranking in the Indian Pharmaceutical Market to 36 at the end of FY15 from 45 in FY13. With APL focusing on new...

Ajanta Pharma Ltd. has an average target of 3022.00 from 5 brokers.

Is Ajanta Pharma Ltd. worth buying?

189 Votes:

Buy 77.25%

Sell 15.87%

Hold 6.88%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf